RUBRACA市場：市場規模、予測、市場洞察-2032年

Clovis Oncologyが開発したRUBRACA（ルカパリブ）は、経口の低分子PARP1、PARP2、PARP3阻害剤であり、卵巣がんや転移性去勢抵抗性前立腺がんなど複数のがん種を対象に、単剤療法および他の抗がん剤との併用療法として開発されています。また、他の腫瘍型に対する探索研究も進行中です。

プラチナ製剤をベースとした化学療法で完全奏効または部分奏効を示した再発上皮性卵巣がん、卵管がん、原発性腹膜がんの成人女性の維持療法に適応されています。BRCA遺伝子変異（生殖細胞系および/または体細胞系）を有する上皮性卵巣がん、卵管がん、原発性腹膜がんで、2種類以上の化学療法を受けた成人女性の治療に適応されます。

今後数年間で、卵巣がんの市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療/改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ルブラカの優位性に影響を与える可能性のある機会を模索しています。卵巣がんを対象とした他の新興製品がルブラカと厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国における卵巣がん治療薬のRUBRACA市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 卵巣がんにおけるRUBRACAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 RUBRACA市場評価

• 卵巣がんにおけるRUBRACAの市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国の卵巣がん治療薬RUBRACA市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: RUBRACA, Clinical Trial Description, 2023
• Table 2: RUBRACA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: RUBRACA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: RUBRACA Market Size in the US, in USD million (2019-2032)
• Table 7: RUBRACA Market Size in Germany, in USD million (2019-2032)
• Table 8: RUBRACA Market Size in France, in USD million (2019-2032)
• Table 9: RUBRACA Market Size in Italy, in USD million (2019-2032)
• Table 10: RUBRACA Market Size in Spain, in USD million (2019-2032)
• Table 11: RUBRACA Market Size in the UK, in USD million (2019-2032)
• Table 12: RUBRACA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: RUBRACA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: RUBRACA Market Size in the United States, USD million (2019-2032)
• Figure 3: RUBRACA Market Size in Germany, USD million (2019-2032)
• Figure 4: RUBRACA Market Size in France, USD million (2019-2032)
• Figure 5: RUBRACA Market Size in Italy, USD million (2019-2032)
• Figure 6: RUBRACA Market Size in Spain, USD million (2019-2032)
• Figure 7: RUBRACA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: RUBRACA Market Size in Japan, USD million (2019-2032)

"RUBRACA Market Size, Forecast, and Drug Insight - 2032" report provides comprehensive insights about RUBRACA for ovarian cancer in the seven major markets. A detailed picture of the RUBRACA for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the RUBRACA for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the RUBRACA market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

RUBRACA (Rucaparib), developed by Clovis Oncology, is an oral, small-molecule inhibitor of PARP1, PARP2, and PARP3, developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anticancer agents. Exploratory studies on other tumor types are also underway.

RUBRACA is approved by US FDA for the following patient segments:-

• It is indicated for the maintenance treatment of adult women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
• It is indicated for the treatment of adult women with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the RUBRACA description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on RUBRACA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the RUBRACA research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around RUBRACA.
• The report contains forecasted sales of RUBRACA for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for RUBRACA in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RUBRACA Analytical Perspective by DelveInsight

• In-depth RUBRACA Market Assessment

This report provides a detailed market assessment of RUBRACA for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• RUBRACA Clinical Assessment

The report provides the clinical trials information of RUBRACA for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence RUBRACA dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to RUBRACA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of RUBRACA in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of RUBRACA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RUBRACA in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of RUBRACA?
• What is the clinical trial status of the study related to RUBRACA in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RUBRACA development?
• What are the key designations that have been granted to RUBRACA for ovarian cancer?
• What is the forecasted market scenario of RUBRACA for ovarian cancer?
• What are the forecasted sales of RUBRACA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to RUBRACA for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. RUBRACA Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. RUBRACA Market Assessment

• 5.1. Market Outlook of RUBRACA in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of RUBRACA in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of RUBRACA in the United States for ovarian cancer
  • 5.3.2. Market Size of RUBRACA in Germany for ovarian cancer
  • 5.3.3. Market Size of RUBRACA in France for ovarian cancer
  • 5.3.4. Market Size of RUBRACA in Italy for ovarian cancer
  • 5.3.5. Market Size of RUBRACA in Spain for ovarian cancer
  • 5.3.6. Market Size of RUBRACA in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of RUBRACA in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options